Market
Average survival extension reported for KIMMTRAK patients by NHS by end of 2025?
2
Resolution / Starting Odds
Less than 3 months • 25%
3 to 6 months • 25%
6 to 9 months • 25%
More than 9 months • 25%
NHS official reports or peer-reviewed medical journals
Story
NHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma
Dec 3, 2024, 07:10 AM
A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.
View original story
Similar markets
1 to 6 months • 25%
Less than 1 month • 25%
More than 12 months • 25%
6 to 12 months • 25%
Less than 50% • 25%
50% to 75% • 25%
76% to 90% • 25%
More than 90% • 25%
Worse Outcomes • 25%
No Change • 25%
Moderate Improvement • 25%
Significant Improvement • 25%
No • 50%
Yes • 50%
Partially recovered • 25%
Deceased • 25%
Fully recovered • 25%
No significant recovery • 25%
No significant effect on lifespan • 25%
Proven effective with significant lifespan extension • 25%
Negative effects or halted trials • 25%
Proven effective with moderate lifespan extension • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Increased lifespan • 25%
Reduced disease incidence • 25%
Improved cellular health • 25%
Other • 25%
Yes • 50%
No • 50%
